Rituximab as First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular LymphomaProfile Report

被引：0
|
作者：
Jamie D. Croxtall
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Maintenance Therapy; Induction Therapy; Follicular Lymphoma; Observation Group; Progressive Multifocal Leukoencephalopathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：329 / 331
页数：2
相关论文
共 50 条
  • [31] Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Calvo, Xavier
    Bobillo, Sabela
    Bruno Montoro, Jose
    Montserrat, Emili
    Bosch, Francesc
    BLOOD, 2013, 122 (24) : 3951 - 3959
  • [32] High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-line Bendamustine Rituximab and Rituximab Maintenance
    Rangel-Patino, Juan
    Kridel, Robert
    Kuruvilla, John
    Prica, Anca
    Kukreti, Vishal
    Bhella, Sita
    Delabie, Jan
    Vijenthira, Abi
    Crump, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S503 - S503
  • [33] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Scullin, DC
    Corso, SW
    Yardley, DA
    Morrissey, L
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4261 - 4267
  • [34] Rituximab maintenance therapy in follicular lymphoma comes of age
    Hiddemann, W
    LEUKEMIA RESEARCH, 2006, 30 : S1 - S2
  • [35] Rituximab maintenance therapy: a step forward in follicular lymphoma
    van Oers, Marinus H. J.
    HAEMATOLOGICA, 2007, 92 (06) : 826 - 833
  • [36] Rituximab maintenance therapy of follicular lymphoma in clinical practice
    Duehrsen, Ulrich
    Broszeit-Luft, Stefanie
    Dieing, Annette
    Lueck, Andreas
    Porowski, Piotr
    Reiser, Marcel
    Schwinger, Ulrike
    Klawitter, Sandra
    Krumm, Katja
    Jentsch-Ullrich, Kathleen
    CANCER MEDICINE, 2018, 7 (07): : 2903 - 2912
  • [37] Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Folio First-Line Therapy in Patients with Follicular Lymphoma
    Chen, Qiushi
    Ayer, Turgay
    Nastoupil, Loretta J.
    Rose, Adam C.
    Flowers, Christopher R.
    VALUE IN HEALTH, 2015, 18 (02) : 189 - 197
  • [38] Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial
    Kahl, Brad S.
    Burke, John M.
    van der Jagt, Richard
    Chang, Julie
    Wood, Peter
    Hawkins, Tim
    MacDonald, David
    Trotman, Judith
    Simpson, David
    Kolibaba, Kathryn S.
    Issa, Samar
    Hallman, Doreen
    Chen, Ling
    Flinn, Ian W.
    BLOOD, 2017, 130
  • [39] Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse
    Michael Adena
    Jennifer Houltram
    Stephen P. Mulligan
    Carlene Todd
    Grace Malanos
    PharmacoEconomics, 2014, 32 : 193 - 207
  • [40] Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine and Rituximab Vs Other Rituximab Combinations in the United States
    Galaznik, Aaron
    Bell, Jill A.
    Hamilton, Laurie
    Ogbonnaya, Augustina
    Hennenfent, Kristin
    Eaddy, Michael T.
    Shou, Yaping
    BLOOD, 2017, 130
12345